Combined 177 Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177 Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing the response and durability-Reference-Cited by-同舟云学术

Combined 177 Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177 Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing the response and durability

Published:2021-09 Issue:15 Volume:81 Page:1225-1234
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Suman Sonam¹²,Parghane Rahul V.¹²,Joshi Amit²³,Prabhash Kumar²³,Talole Sanjay²⁴,Basu Sandip¹²^ORCID

Affiliation:

1. Radiation Medicine Centre, Bhabha Atomic Research Centre Tata Memorial Centre Annexe Mumbai India

2. Homi Bhabha National Institute Mumbai India

3. Department of Medical Oncology Tata Memorial Centre Mumbai India

4. Department of Biostatistics Tata Memorial Centre Mumbai India

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24219

Reference23 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Treatment of Advanced Prostate Cancer

3. Towards personalizing treatment strategies in mCRPC: can dual‐tracer PET/CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision‐making (between chemotherapy, second‐generation anti‐androgens and PSMA‐directed radioligand therapy) early in the disease course?;Basu S;Eur J Nucl Med Mol Imaging,2020

4. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

5. Systemic Radioligand Therapy with 177 Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer;Journal of Clinical Medicine;2024-08-06

2. Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium;Journal of Experimental & Clinical Cancer Research;2024-07-17

3. Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer;Cancers;2024-07-12

4. Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review;Cancers;2024-01-25

5. Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies;Current Oncology Reports;2023-10-20